59 North Communications
Quotes
Share:
Subscribe:
news.cision.com
/
59 North Communications
/
First gastroesophageal cancer patients enrolled in Phase 2 basket trial using Affibody’s PET imaging agent ABY-025
/
David Bejker, CEO
2 of 2
David Bejker, CEO
Tue, Mar 26, 2024 09:14 CET
Low resolution
Medium resolution
Original resolution
Subscribe
Related Releases
Positive Phase 3 Results in Hidradenitis Suppurativa Further Strengthen Competitive Profile of Izokibep
Wed, Aug 14, 2024 08:30 CET
